The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Bisphosphonates are effective in the management of bone disease in patients with multiple myeloma and recent reports have suggested that they may also have an anti-tumour activity. In support of this, we have previously demonstrated that bisphosphonates can induce myeloma cell apoptosis in vitro; ho...

Ամբողջական նկարագրություն

Մատենագիտական մանրամասներ
Հիմնական հեղինակներ:	Shipman, C, Vanderkerken, K, Rogers, M, Lippitt, J, Asosingh, K, Hughes, D, Van Camp, B, Russell, R, Croucher, P
Ձևաչափ:	Journal article
Լեզու:	English
Հրապարակվել է:	2000

Նմանատիպ նյութեր

Bisphosphonates--mechanisms of action in multiple myeloma.
‌: Shipman, C, և այլն
Հրապարակվել է: (2000)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
‌: Croucher, P, և այլն
Հրապարակվել է: (2003)

Bisphosphonates and in vivo models of multiple myeloma - Reply
‌: Shipman, C, և այլն
Հրապարակվել է: (2001)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
‌: Vanderkerken, K, և այլն
Հրապարակվել է: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
‌: Croucher, P, և այլն
Հրապարակվել է: (2001)

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
‌: Shipman, C, և այլն
Հրապարակվել է: (1997)

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
‌: Shipman, C, և այլն
Հրապարակվել է: (1998)

Anti-tumour activity of bisphosphonates in human myeloma cells.
‌: Shipman, C, և այլն
Հրապարակվել է: (1998)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
‌: Croucher, P, և այլն
Հրապարակվել է: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
‌: Croucher, P, և այլն
Հրապարակվել է: (2001)

Osteoprotegerin and the development of myeloma bone disease
‌: Croucher, P, և այլն
Հրապարակվել է: (2004)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
‌: Croucher, P, և այլն
Հրապարակվել է: (2002)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
‌: Croucher, P, և այլն
Հրապարակվել է: (2001)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
‌: Croucher, P, և այլն
Հրապարակվել է: (2002)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
‌: Shipman, C, և այլն
Հրապարակվել է: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
‌: Shipman, C, և այլն
Հրապարակվել է: (2002)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
‌: Mueller, G, և այլն
Հրապարակվել է: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
‌: Mueller, G, և այլն
Հրապարակվել է: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
‌: Shipman, C, և այլն
Հրապարակվել է: (2002)

Nitrogen-containing bisphosphonates induce apoptosis in human bone marrow-derived myeloma cells in vitro by inhibiting protein prenylation.
‌: Gordon, S, և այլն
Հրապարակվել է: (1999)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
‌: Edwards, C, և այլն
Հրապարակվել է: (2007)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
‌: De Leenheer, E, և այլն
Հրապարակվել է: (2004)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
‌: Shipman, C, և այլն
Հրապարակվել է: (2000)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
‌: De Leenheer, E, և այլն
Հրապարակվել է: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
‌: Croucher, P, և այլն
Հրապարակվել է: (2003)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
‌: Locklin, R, և այլն
Հրապարակվել է: (2005)

The bisphosphonate-ester apornine does not act by inhibiting protein prenylation, but enhances the effects of lovastatin on myeloma cells
‌: Roelofs, A, և այլն
Հրապարակվել է: (2006)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
‌: Richard Derman, և այլն
Հրապարակվել է: (2009-09-01)

Osteoblasts protect multiple myeloma cells from T-cell-induced apoptosis
‌: Locklin, R, և այլն
Հրապարակվել է: (2007)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
‌: Liesbeth Bieghs, և այլն
Հրապարակվել է: (2010-01-01)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
‌: Shipman, C, և այլն
Հրապարակվել է: (2002)

The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia
‌: Nutrisia Aquariushinta Sayuti, և այլն
Հրապարակվել է: (2020-09-01)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
‌: Shipman, C, և այլն
Հրապարակվել է: (2003)

Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
‌: Clive Henry Buckle, և այլն
Հրապարակվել է: (2012-01-01)

Administration of bisphosphonate (ibandronate) impedes molar tooth movement in rabbits: A radiographic assessment
‌: V Venkataramana, և այլն
Հրապարակվել է: (2014-01-01)

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
‌: Jagdev, S, և այլն
Հրապարակվել է: (2001)

NE10790, a phosphonocarboxylate analogue of risedronate, induces human myeloma cell apoptosis in vitro
‌: Roelofs, A, և այլն
Հրապարակվել է: (2004)

Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment.
‌: Locklin, R, և այլն
Հրապարակվել է: (2007)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
‌: Maria Nieves Lopez Muñoz, և այլն
Հրապարակվել է: (2023-08-01)

Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients
‌: Blum Christina, և այլն
Հրապարակվել է: (2010-07-01)